BioMarin Pharmaceutical Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/10/2026)
| Balance Sheet | Total Assets | 7,594,020,000.00 | ROE | 80.16 % |
| Balance Sheet | Total Equity | 6,087,000,000.00 | ROA | 4.59 % |
| Cashflow | Capital Expenditures | -103,038,000.00 | P/FCF | 14.58 |
| Cashflow | Free Cash Flow | 724,956,032.00 | – | – |
| Cashflow | Operating Cash Flow | 827,994,000.00 | P/CF | 12.76 |
| Income | Earnings per Share (diluted) | 1.80 | Div. Yield | – |
| Income | Net Income | 348,901,000.00 | P/E | 30.63 |
| Income | Shares Outstanding | 191,639,000.00 | P/B | 1.74 |
| Income | Total Revenue | 3,221,250,000.00 | P/S | 3.28 |
Ratios calculated on: 10/14/2026
Company Description
BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company's product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). It is conducting clinical trials on several product candidates for the treatment of various diseases. They include Vimizim (formerly referred to as GALNS), an enzyme replacement therapy for the treatment of Mucopolysaccharidosis Type IV or Morquio Syndrome Type A (MPS IV A), PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU), and BMN-701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder. On January 7, 2013, the Company acquired Zacharon Pharmaceuticals.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.biomarin.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more